Clinical trials: Esophagogastric Junction Disorder
Gastro Esophageal Junction Cancer, Stomach Cancer
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
- Conditions
- Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
- Trial name
- NCT03488667
- Testing
- Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Esophageal Neoplasms
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage…
- Trial name
- NCT00153881
- Testing
- Capecitabine (Xeloda)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01243398
- Testing
- quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- University of Oxford
Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy
A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers
This is a single-arm, multicenter, phase 2 study to assess the efficacy and safety of Toripalimab Injection (JS001) in patients with advanced recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma who have…
- Trial name
- NCT04603040
- Testing
- Toripalimab
- Where
- 39 sites in China
- Volunteers
- 17 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Solid Tumor, Colorectal Cancer (CRC)
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
- Conditions
- Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- ODIN (NCT07151040)
- Testing
- TH9619
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 43 people
- Sponsor
- One-carbon Therapeutics AB
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06131840
- Testing
- PF-08046050, bevacizumab, 5-Fluorouracil (5-FU)
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 914 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Gastric (Stomach) Cancer, GastroEsophageal Cancer
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC/GEJ and advanced CLDN18.2+ PDAC.
- Conditions
- Gastric (Stomach) Cancer, GastroEsophageal Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
- Trial name
- NCT07481357
- Testing
- DA-3501
- Where
- 3 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- Dong-A ST Co., Ltd.
Gastric Cancer, Gastroesophageal-junction Cancer
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal…
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Trial name
- NCT05539430
- Testing
- LB1908
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- Legend Biotech USA Inc
Gastric Cancer, Gastroesophageal Junction Cancer
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing…
- Trial name
- NCT06346392
- Testing
- AZD0901, Ramucirumab+ paclitaxel, Paclitaxel
- Where
- 158 sites in United States, Brazil and 17 more
- Volunteers
- 594 people
- Sponsor
- AstraZeneca
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
There is an unmet medical need to treat people with advanced cancer in the stomach and the junction area where the stomach joins the food pipe.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07829757
- Testing
- Zolbetuximab, Oxaliplatin, Folinic Acid
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Esophagus Cancer, Esophagogastric Junction Cancer
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients.
- Conditions
- Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy
- Trial name
- NCT04821778
- Testing
- Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy
- Where
- 5 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma
Perioperative chemotherapy with the FLOT regimen (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) is a standard treatment for resectable gastric and gastroesophageal junction adenocarcinoma.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
- Trial name
- NCT07859254
- Testing
- FLOT Chemotherapy
- Where
- Colombia
- Volunteers
- 90 people
- Sponsor
- Fundación Santa Fe de Bogota
Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer
Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites
To evaluate the efficacy and safety of retlirafusp alfa in combination with SOX chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with…
- Conditions
- Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant
- Trial name
- NCT07855757
- Testing
- Retlirafusp Alfa + SOX + Intraperitoneal Nab-Paclitaxel
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Zhejiang Cancer Hospital
Barrett's Esophagus
Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
The specific aim of this study is to determine the accuracy of Optical Coherence Tomography (OCT) imaging for screening and diagnosis of the distal esophagus in patients undergoing a clinical esophagogastroduodenoscopy (EGD)…
- Trial name
- NCT01401699
- Testing
- Optical Frequency Domain Imaging (OFDI)
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Massachusetts General Hospital
Gastric Cancer
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis…
- Trial name
- NCT04354662
- Testing
- Toripalimab, Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HER2-positive Gastric Cancer, Metastatic Gastric Cancer
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
This is a Phase II, randomized, multicenter, open-label clinical trial designed to compare Disitamab Vedotin plus Sintilimab and S-1 with Trastuzumab plus chemotherapy ± Sintilimab for first-line treatment of HER2-Positive…
- Conditions
- HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
- Trial name
- NCT06730373
- Testing
- Disitamab Vedotin, Sintilimab, S-1
- Where
- 20 sites in China
- Volunteers
- 110 people
- Sponsor
- Qilu Hospital of Shandong University
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Stomach Cancer, Gastroesophageal Junction Cancer
FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer
Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of Herceptin and pertuzumab in combination with FLOT in the perioperative treatment of resectable…
- Trial name
- PETRARCA (NCT02581462)
- Testing
- FLOT alone, FLOT + Herceptin/Pertuzumab
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Stomach Neoplasms, Esophageal Neoplasms
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer.
- Trial name
- NCT00515216
- Testing
- 5-fluorouracil, Oxaliplatin, Leucovorin
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Vanderbilt University
Stomach Neoplasms, Immune Checkpoint Inhibitors
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
This is a multicenter, randomized, phase 2 trial to investigate the efficacy and safety of serlulimab combined with nab-paclitaxel plus SOX versus nab-paclitaxel plus SOX alone as neoadjuvant treatment for locally advanced GC or…
- Trial name
- NCT06576921
- Testing
- Serplulimab Combined With Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 116 people
- Sponsor
- Xijing Hospital